All In Biotech

Drug Trial Radar · NCT06744868

A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects

A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects: A Randomized, Bouble-Blind, Placebo-Controlled Phase I Trial

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Dec 19, 2023

Primary completion

Sep 22, 2024

Study completion Sep 22, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study includes single-ascending dose cohorts (SAD cohorts) and multiple-ascending dose cohorts (MAD cohorts). The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of THDBH120 injection in healthy patients.

Conditions

  • Healthy

Interventions

  • THDBH120 injection (SAD)Drug

    Participants received escalating single doses of THDBH120 by subcutaneous injection.

  • Placebo of THDBH120 injection (SAD)Drug

    Participants received single dose of placebo by subcutaneous injection.

  • THDBH120 injection (MAD)Drug

    Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.

  • Placebo of THDBH120 injection (MAD)Drug

    Participants received placebo once weekly for four weeks by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)Time frame: From the first drug administration to the follow-up visit (57 days after the last drug administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.